Stealth BioTherapeutics (NASDAQ:MITO) Announces Earnings Results, Beats Estimates By $0.04 EPS

Stealth BioTherapeutics (NASDAQ:MITO) announced its earnings results on Wednesday. The company reported ($0.04) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.04, Fidelity Earnings reports.

NASDAQ:MITO traded up $0.22 on Friday, reaching $12.17. 696 shares of the company’s stock traded hands, compared to its average volume of 5,312. The stock’s 50-day moving average is $12.24. The stock has a market capitalization of $434.37 million and a price-to-earnings ratio of -8.63. Stealth BioTherapeutics has a 12 month low of $10.70 and a 12 month high of $20.99.

A number of brokerages recently commented on MITO. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Stealth BioTherapeutics in a report on Friday, July 12th. Zacks Investment Research cut Stealth BioTherapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 18th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Stealth BioTherapeutics currently has a consensus rating of “Buy” and a consensus price target of $24.83.

Stealth BioTherapeutics Company Profile

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.

See Also: Does a trade war provide a risk to the global economy?

Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with's FREE daily email newsletter.